CreativeOne Wealth LLC Has $958,000 Holdings in Merck & Co., Inc. (NYSE:MRK)

CreativeOne Wealth LLC lowered its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 7.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 8,790 shares of the company’s stock after selling 735 shares during the quarter. CreativeOne Wealth LLC’s holdings in Merck & Co., Inc. were worth $958,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Bare Financial Services Inc bought a new position in Merck & Co., Inc. in the 4th quarter valued at about $28,000. Rakuten Securities Inc. purchased a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $30,000. RIA Advisory Group LLC bought a new position in Merck & Co., Inc. during the 4th quarter valued at $30,000. AlphaMark Advisors LLC purchased a new position in Merck & Co., Inc. during the 4th quarter worth $34,000. Finally, Valued Wealth Advisors LLC bought a new stake in shares of Merck & Co., Inc. in the 4th quarter worth $42,000. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK stock traded up $0.47 during trading hours on Wednesday, reaching $131.23. The stock had a trading volume of 683,592 shares, compared to its average volume of 7,973,293. The stock’s fifty day simple moving average is $127.60 and its 200 day simple moving average is $119.23. The company has a current ratio of 1.25, a quick ratio of 0.99 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $332.38 billion, a PE ratio of 145.31, a PEG ratio of 1.68 and a beta of 0.39. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $133.10.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last released its quarterly earnings results on Thursday, April 25th. The company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The firm had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. During the same period in the previous year, the business earned $1.40 EPS. The business’s revenue for the quarter was up 8.9% on a year-over-year basis. On average, equities research analysts predict that Merck & Co., Inc. will post 8.69 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Barclays boosted their price target on shares of Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. TheStreet cut Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research note on Monday, March 4th. UBS Group boosted their price target on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the stock a “buy” rating in a report on Friday, February 2nd. StockNews.com raised shares of Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a report on Friday, February 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $135.00 price target on shares of Merck & Co., Inc. in a research note on Thursday, April 18th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Merck & Co., Inc. currently has a consensus rating of “Moderate Buy” and an average price target of $131.33.

Check Out Our Latest Analysis on MRK

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.